Regulatory Focus™ > News Articles > In Focus: Doing Business in Asia

In Focus: Doing Business in Asia

Posted 01 February 2009 | By Mukesh Kumar

Asia shines as a beacon of hope in an era when increasing development costs, shrinking pipelines, decreasing revenues and more-demanding clinical trials dominate discussions in the pharmaceutical industry. A recent report from the PricewaterhouseCooper's Health Research Institute,1 projects Asia to be the "Land of Golden Opportunities" that provides high-quality, inexpensive labor, and an increasingly favorable market for pharmaceuticals. Similar projections have been made by other financial and industry experts.2,3

 

© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe